Navigation Links
In a fight to the finish, Saint Louis University research aims knockout punch at hepatitis B
Date:2/4/2013

fit, but it should serve the same function."

Once the assay for the RNAseH was developed, Tavis and his team were able to try out this theory.

"We found that what worked with the first enzyme worked with the second enzyme," Tavis said. "This is a proof of principle. We're on the right track."

Tavis now has a measuring tool and evidence that a number of the techniques that stopped HIV, including inhibitors of HIV RNAseH, could also inhibit the hepatitis B virus RNAseH, showing that the parallels held true. From there, Tavis and his team went on to prove that hepatitis B replication could in fact be stopped in cells with drugs that targeted the elusive second enzyme, RNAseH.

Hope on the Horizon

With these promising advances, researchers say that the search for anti-hepatitis B RNAseH drugs is now feasible and that using similar anti-HIV compounds as a guide is likely to have a high chance of success.

The research team's next step will be to study several variations of hepatitis B virus, different genotypes of the virus, to be able to measure and study the RNAseH enzyme in all forms of the virus. Current findings demonstrated success in only some genotypes. Findings from the current study suggest some promising avenues as researchers will now attempt to block RNAseH in the two most common genotypes, B and C.

In addition, researchers will aim to improve the strength and speed of the RNAseH assay for high throughput screening, a process for rapidly screening many thousands of compounds. These developments will clear the way for full-scale antiviral drug discovery.

Investigators have reason to hope that combining a new anti-hepatitis B RNAseH drug with the existing drugs may suppress the virus far enough to cure patients with hepatitis B.

"I anticipate a new drug targeting the second enzyme would be used together with the existing drugs," Tavis said. "They jam different parts of the
'/>"/>

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. UC research: Tracking Lake Erie water snake in fight against invasive fish
2. Young researcher taking fight against global killer to the next level in Vietnam
3. Evolving to fight epidemics: Weakness can be an advantage
4. Preventing home invasions means fighting side-by-side for coral-dwelling crabs and shrimp
5. Study shows botanical formula fights prostate cancer
6. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
7. Study finds cancer-fighting goodness in cholesterol
8. Trial launched into curry chemicals cancer-fighting properties
9. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
10. Biosensor illuminates compounds to aid fight against TB
11. Fighting bacterias strength in numbers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Infectious Diseases (NIAID), part of the National Institutes of ... to Tulane University for its ongoing efforts to treat ... that threatens hundreds of thousands of people annually in ... threat. The contract will include collaboration between Tulane; ...
... are going on a diet, while others have expanding ... rising temperatures due to global climate change, speculates Prof. ... who has been measuring the evolving body sizes of ... most extreme. , Changes are happening primarily in higher ...
... (February 5, 2010) New research from the Hood Center for ... first time sheds light on the significant potential negative impact ... on children. The study, which appears in the current ... of the "brand placements" for food, beverage, and food retail ...
Cached Biology News:Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Animals cope with climate change at the dinner table 2New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
(Date:6/1/2015)... South Korea , June 1, 2015 ... Cross Biotherapeutics Inc. (GCBT) kicked off construction today on ... Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project represents ... Canada in the biopharmaceutical industry, ... immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... , June 1, 2015 GenomeDx ... genomic analysis platform, successfully classified various subtypes ... expression of certain biomarkers, including one type ... this unique genomic signature has potential as ... neoadjuvant chemotherapy in patients with muscle-invasive bladder ...
(Date:6/1/2015)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced ... complete 2015 first quarter financial statements and MD&A have been filed ... March 31,(in CDN$,000 except per share data) , 2015 ... 1,974 Gross profit , 1,531 , 329 Ebitda* ... 528 , (531) Basic earnings (loss) per share ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... YORK, Feb. 11 VaxGen, Inc. (Pink Sheets:,VXGN), WHAT: Jim Panek, CEO ... provide an update on Raven,s oncology ... plans and prospects for the new Company., WHEN: 2:45 ... webcast of the presentation, go to VaxGen@BIOCEO, ...
... - ... Raised - - Conference Call to be Held ... Uroplasty, Inc. (Amex:,UPI), a medical device company that develops, manufactures and markets,innovative ... of $3.7 million for the third quarter of,fiscal 2008 ended December 31, ...
... SAN FRANCISCO, Calif., Feb. 8 Anesiva,Inc. (Nasdaq: ... Janney to,the company,s board of directors. Mr. Janney previously ... when he transitioned off,the board following the merger of ... contributor to the Anesiva board of directors,and we are ...
Cached Biology Technology:VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 2VaxGen to Present at the 10th Annual BIO CEO and Investor Conference 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 2Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 4Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 5Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 6Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 7Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 8Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 9Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 10Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: